Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06953739 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.

Name: A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. — clinical trial record (NCT06953739)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorThe First Affiliated Hospital with Nanjing Medical University

Started2025-05-01

View on ClinicalTrials.gov ↗

The First Affiliated Hospital with Nanjing Medical University

275 trials monitored

See 6 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

Extranodal natural-killer (NK)/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis. Notably, patients with advanced-stage disease or early-stage non-upper aero-digestive tract (NUAT) involvement frequently develop hemophagocytic lymphohistiocytosis (HLH), necessitating more effective therapeutic interventions. This Multicenter, Randomized Controlled Clinical Study aimed to compare the efficacy and safety of P-GEMD and P-Gemox in the treatment of newly diagnosed early NUAT or advanced-stage ENKTL.

Trial Details

NCT Number	NCT06953739
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	NK-T-Cell Lymphoma, Extranodal
Enrollment	60 participants
Start Date	2025-05-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-01